Related Experiment Video
Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgens and prevention of prostate cancer
Jamey A Sarvis1, Ian M Thompson
1University of Texas Health Science Center, San Antonio, Texas 78229-3900, USA.
Purpose Of Review:
This review provides a description of recent insights into the role of androgens in prostate cancer prevention.
Recent Findings:
Many studies have elucidated a variety of molecular mechanisms involved in the initiation and progression of prostate cancer with many directly or indirectly related to the androgen signaling pathway. Both well known and novel agents for targeting the androgen pathway are under investigation, though very few are in clinical trials. After a review of recent papers describing these mechanisms, their results and implications were summarized.
Summary:
Finasteride remains the only agent proven to reduce the risk of prostate cancer, though there are currently two other ongoing phase III trials with vitamin E, selenium, and dutasteride. An enhanced understanding of complex interactions with the androgen pathways is leading to the exploration of additional promising approaches to mitigating the risk of prostate cancer.
Insights
Finasteride is the only proven agent for prostate cancer risk reduction. Ongoing trials explore vitamin E, selenium, and dutasteride, alongside a deeper understanding of androgen pathways for new prevention strategies.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Prostate cancer development is intricately linked to the androgen signaling pathway.
- Understanding these molecular mechanisms is crucial for effective prevention strategies.
Purpose of the Study:
- To review recent advancements in understanding the role of androgens in prostate cancer prevention.
- To summarize novel and established therapeutic targets within the androgen pathway.
Main Methods:
- Comprehensive literature review of recent studies on androgen signaling in prostate cancer.
- Analysis of molecular mechanisms, therapeutic agents, and clinical trial data.
Main Results:
- Numerous molecular mechanisms in prostate cancer initiation and progression involve the androgen pathway.
- While many agents target this pathway, few have reached clinical trials.
- Finasteride is the sole agent currently proven to reduce prostate cancer risk.
Conclusions:
- Ongoing phase III trials are investigating vitamin E, selenium, and dutasteride for prostate cancer prevention.
- Advances in understanding androgen pathway interactions are paving the way for novel risk mitigation approaches.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Cancer Prevention
Some...
Cancer Prevention
Some...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Testosterone: Functions and Regulation
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
